BioStrand Acquired by IPA

BioStrand Announces Acquisition by IPA –

Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence

 

DIEPENBEEK, BELGIUM, March 29th, 2022 – BioStrand BV is pleased to announce that it has entered into a definitive share purchase agreement (SPA) to be acquired by IPA (ImmunoPrecise Antibodies Ltd.), through IPA’s wholly-owned subsidiary ImmunoPrecise Netherlands B.V. IPA will gain control over BioStrand BV, BioKey BV, and BioClue BV (hereinafter collectively referred to as “BioStrand”).

This transaction is expected to create short and long-term commercialization opportunities with clients and partners by introducing a novel AI-powered protein-protein interactions prediction platform and fortifying IPA’s sequencing with massive throughput capabilities in omics (genomics, transcriptomics, proteomics, and metabolomics) interrogation. BioStrand anticipates that the transaction will not only attract new clients and partners but will also create a powerful synergy with IPA’s subsidiary, Talem Therapeutics. in therapeutic antibody development.

 

Company Synergies

The acquisition of BioStrand expands IPA’s scientific capabilities to excel far beyond antibody discovery, expanding from the earliest stages of target identification to late-stage therapies. The transaction combines BioStrand’s computer-aided drug discovery capabilities with IPA’s best-in-class antibody discovery and development expertise to create an integrated, next-generation, end-to-end platform for target and therapeutic antibody discovery and early drug development.

Dr. Ingrid Brands, Director and Chief Executive Officer of BioStrand, commented, “combining the unique offering of IPA as a leading, early-stage antibody discovery contract research organization with BioStrand’s next-generation capabilities in systems omics analysis creates a great synergy and will revolutionize the approach for target and antibody discovery. We are excited to join the IPA family. IPA’s innovative attitude and BioStrand’s out-of-the box way of thinking will boost developments. Once our platforms are integrated, we will be able to attract new business opportunities and provide clients with unparalleled advantages in their discovery programs. The synergy with Talem will also create numerous in-house opportunities for early drug development.”

 

 

About ImmunoPreciseAntibodies Ltd.

ImmunoPrecise Antibodies Ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. The Company offers a hybrid of services and programs with advanced platforms and technologies — dynamic scientists and business advisors— to optimize antibody discovery and development, against rare and/or challenging epitopes. For further information, visit www.immunoprecise.com.

 

About BioStrand BV

BioStrand BV offers an AI-powered revolutionary methodology for rapidly analyzing and mining a broad range of biological data to identify patterns and variations in multi-omics data and detect structural anchor points that will drive innovation in numerous fields including precision medicine, drug and vaccine development, and target discovery. For further information, visit www.biostrand.be

 

About BioKey BV

The business of BioKey BV focuses on technology, in the field of bioinformatics and biotechnology, related to the identification of characteristic biological sequences in proteins, RNA and DNA, and their different information layers, the development of a knowledgebase containing these characteristic biological sequences and information layers, and the use of this database to process biological sequences and compare the processed biological sequences.

 

About BioClue BV

The business of BioClue BV focuses on technology, in the field of bioinformatics and biotechnology, for performing, inherently linked with a microarray process and possible primary analysis, a secondary analysis, whether or not performed simultaneously with the primary analysis, consisting of read mapping, read assembly – de novo or reference based – and immediate identification of variations, as well as on products, services and tools related to the developed technology, primarily aimed at determining biological sequences in proteins, RNA and DNA, including through mass spectrometry, sequencing, micro array or hybrid microarray system technologies.